We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AbbVie's (ABBV) Rinvoq Meets Goal in Ulcerative Colitis Study
Read MoreHide Full Article
AbbVie Inc. (ABBV - Free Report) announced that the phase III induction study – U-ACHIEVE, which evaluated its promising JAK inhibitor Rinvoq (upadacitinib), for treating adult patients with moderate to severe ulcerative colitis, has met the primary endpoint.
The U-ACHIEVE study is the first of two phase III induction studies which are investigating the safety and efficacy of once daily Rinvoq (45 mg) for the given indication. Data from the study showed that 26% of patients who were treated with Rinvoq achieved clinical remission – the primary endpoint as compared to only 5% patients who received placebo.
Moreover, the study also met all ranked secondary endpoints, including clinical, endoscopic and histologic outcomes. 36% of patients who were treated with Rinvoq achieved endoscopic improvement compared to only 7% patients who received placebo at week 8 of treatment. Also, 30% of patients who received Rinvoq achieved histologic-endoscopic mucosal improvement versus 7% of patients in the placebo arm at week 8 of treatment.
Importantly, the safety profile of Rinvoq was similar to data from previous studies and no new safety risks were observed.
Shares of AbbVie have rallied 22.7% so far this year compared with the industry’s increase of 4%.
Rinvoq was approved in 2019 for treating moderate-to-severe rheumatoid arthritis (RA).
Apart from ulcerative colitis, Rinvoq is being evaluated in several studies for endoscopic improvement.
Meanwhile, regulatory applications seeking approval for Rinvoq to treat adult patients with active ankylosing spondylitis, active psoriatic arthritis as well as moderate-to-severe atopic dermatitis, are already under review in the United States and Europe.
Rinvoq generated sales of $450 million in the first nine months of 2020. AbbVie expects Rinvoq’s global revenues to be approximately $700 million for the current year. A further label expansion will significantly boost Rinvoq’s sales in the days ahead.
We note that Rinvoq, along with AbbVie’s another immunology drug, Skyrizi (risankizumab), might be the catalyst for AbbVie’s growth in the long run and could offset the potential decline in Humira’s sales following the launch of its biosimilars in the United States, scheduled for 2023. In the European Union, several biosimilars of Humira have already been launched by the likes of Amgen (AMGN - Free Report) , Biogen (BIIB - Free Report) and Novartis’ (NVS - Free Report) generic subsidiary, Sandoz, which is eroding the international sales of Humira.
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.4% per year.
These 7 were selected because of their superior potential for immediate breakout.
Image: Shutterstock
AbbVie's (ABBV) Rinvoq Meets Goal in Ulcerative Colitis Study
AbbVie Inc. (ABBV - Free Report) announced that the phase III induction study – U-ACHIEVE, which evaluated its promising JAK inhibitor Rinvoq (upadacitinib), for treating adult patients with moderate to severe ulcerative colitis, has met the primary endpoint.
The U-ACHIEVE study is the first of two phase III induction studies which are investigating the safety and efficacy of once daily Rinvoq (45 mg) for the given indication. Data from the study showed that 26% of patients who were treated with Rinvoq achieved clinical remission – the primary endpoint as compared to only 5% patients who received placebo.
Moreover, the study also met all ranked secondary endpoints, including clinical, endoscopic and histologic outcomes. 36% of patients who were treated with Rinvoq achieved endoscopic improvement compared to only 7% patients who received placebo at week 8 of treatment. Also, 30% of patients who received Rinvoq achieved histologic-endoscopic mucosal improvement versus 7% of patients in the placebo arm at week 8 of treatment.
Importantly, the safety profile of Rinvoq was similar to data from previous studies and no new safety risks were observed.
Shares of AbbVie have rallied 22.7% so far this year compared with the industry’s increase of 4%.
Rinvoq was approved in 2019 for treating moderate-to-severe rheumatoid arthritis (RA).
Apart from ulcerative colitis, Rinvoq is being evaluated in several studies for endoscopic improvement.
Meanwhile, regulatory applications seeking approval for Rinvoq to treat adult patients with active ankylosing spondylitis, active psoriatic arthritis as well as moderate-to-severe atopic dermatitis, are already under review in the United States and Europe.
Rinvoq generated sales of $450 million in the first nine months of 2020. AbbVie expects Rinvoq’s global revenues to be approximately $700 million for the current year. A further label expansion will significantly boost Rinvoq’s sales in the days ahead.
We note that Rinvoq, along with AbbVie’s another immunology drug, Skyrizi (risankizumab), might be the catalyst for AbbVie’s growth in the long run and could offset the potential decline in Humira’s sales following the launch of its biosimilars in the United States, scheduled for 2023. In the European Union, several biosimilars of Humira have already been launched by the likes of Amgen (AMGN - Free Report) , Biogen (BIIB - Free Report) and Novartis’ (NVS - Free Report) generic subsidiary, Sandoz, which is eroding the international sales of Humira.
Zacks Rank
AbbVie currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.4% per year.
These 7 were selected because of their superior potential for immediate breakout.
See these time-sensitive tickers now >>